Technical Analysis for DERM - Dermira, Inc.

Grade Last Price % Change Price Change
grade D 8.23 4.05% 0.32
DERM closed up 4.05 percent on Friday, August 16, 2019, on 66 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical DERM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Outside Day Range Expansion 0.00%
BB Squeeze Ended Range Expansion 4.05%
Fell Below 20 DMA Bearish 0.37%
Bollinger Band Squeeze Range Contraction 0.37%
Calm After Storm Range Contraction 0.37%
20 DMA Support Bullish -3.63%
Bollinger Band Squeeze Range Contraction -3.63%
Calm After Storm Range Contraction -3.63%
BB Squeeze Started Range Contraction -3.63%

Older signals for DERM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company's late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biopharmaceutical Psoriasis Acne Immunosuppressants Dermatology Skin Cutaneous Conditions Hyperhidrosis Inflammatory Skin Diseases Treatment Of Inflammatory Skin Diseases
Is DERM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.48
52 Week Low 5.9997
Average Volume 681,034
200-Day Moving Average 9.5578
50-Day Moving Average 8.8956
20-Day Moving Average 8.3175
10-Day Moving Average 8.22
Average True Range 0.481
ADX 16.31
+DI 24.2298
-DI 22.8529
Chandelier Exit (Long, 3 ATRs ) 7.957
Chandelier Exit (Short, 3 ATRs ) 8.883
Upper Bollinger Band 8.9205
Lower Bollinger Band 7.7145
Percent B (%b) 0.43
BandWidth 14.499549
MACD Line -0.1815
MACD Signal Line -0.2088
MACD Histogram 0.0273
Fundamentals Value
Market Cap 343.72 Million
Num Shares 41.8 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -3.05
Price-to-Sales 43.67
Price-to-Book 2.90
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.09
Resistance 3 (R3) 9.05 8.74 8.94
Resistance 2 (R2) 8.74 8.52 8.75 8.89
Resistance 1 (R1) 8.48 8.38 8.61 8.52 8.85
Pivot Point 8.17 8.17 8.23 8.18 8.17
Support 1 (S1) 7.91 7.95 8.04 7.95 7.61
Support 2 (S2) 7.60 7.81 7.61 7.57
Support 3 (S3) 7.34 7.60 7.52
Support 4 (S4) 7.38